l-Dopa reverses the effects of MPP+ toxicity
- 1 March 1986
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 88 (3) , 401-402
- https://doi.org/10.1007/bf00180846
Abstract
The behavioral and neurochemical consequences of the intrastriatal administration of 1-methyl-4-phenylpyridinium ion (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), were evaluated using the shuttlebox avoidance paradigm. MPP+ caused a significant depletion of striatal dopamine and significant disruption of shuttlebox performance. L-Dopa administration reversed both the dopamine depletion and the behavioral deficits. These observations are discussed in reference to the rodent-MPTP model of Parkinson's disease.This publication has 7 references indexed in Scilit:
- IV. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effectsLife Sciences, 1985
- Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitorsNature, 1984
- Tolerance following the repeated administration of high doses of phencyclidine: No relation to central catecholamine depletionDrug and Alcohol Dependence, 1984
- A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Proceedings of the National Academy of Sciences, 1983
- Chronic parkinsonism secondary to intravenous injection of meperidine analoguesPsychiatry Research, 1979
- Temporary and partial antagonism by l-DOPA of reserpine-induced suppression of a conditioned avoidance responsePsychopharmacology, 1963